VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CNACNA Financial Corporation
$48.36$13.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCNAFinancials

CNA Financial Corporation (CNA) Financials

30Y historyFree accessUpdated daily

Revenue growth has decelerated to 3.0% as of 2026Q1, though the company maintains underwriting discipline with a 91.8% combined ratio despite historical volatility.

CNA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue14.82B14.71B14B13.13B11.89B11.55B10.69B10.77B10.13B9.54B9.37B9.1B9.69B9.93B9.36B8.95B9.21B8.47B7.8B9.88B10.38B9.86B9.92B11.71B12.29B13.1B15.41B16.29B17.09B17.2B16.99B
Revenue Growth %4.51%5.1%6.66%10.38%2.99%8.04%-0.74%6.25%6.2%1.88%2.91%-6.1%-2.42%6.07%4.64%-2.82%8.7%8.63%-21.1%-4.73%5.21%-0.62%-15.29%-4.7%-6.14%-15%-5.44%-4.67%-0.62%1.24%15.57%
Medical Costs & Claims9.87B10.19B9.54B8.71B8.14B7.81B7.58B7.19B6.91B6.54B6.52B6.92B6.91B7.17B7B6.67B4.99B5.29B5.72B7.53B7.58B8.54B8.13B11.88B10.18B13.19B11.71B14.04B13.9B13.65B13.56B
Medical Cost Ratio %66.6%69.27%68.12%66.38%68.48%67.68%70.93%66.77%68.16%68.57%69.59%76.08%71.28%72.17%74.79%74.48%54.13%62.44%73.38%76.17%73.06%86.62%81.87%101.42%82.84%100.69%76.01%86.19%81.3%79.37%79.84%
Gross Profit4.95B4.52B4.46B4.41B3.75B3.73B3.11B3.58B3.23B3B2.85B2.18B2.78B2.76B2.36B2.28B4.22B3.18B2.08B2.36B2.79B1.32B1.8B-166M2.11B-90M3.7B2.25B3.2B3.55B3.43B
Gross Margin %33.4%30.73%31.88%33.62%31.52%32.32%29.07%33.23%31.84%31.43%30.41%23.92%28.72%27.83%25.21%25.52%45.87%37.56%26.62%23.83%26.94%13.38%18.13%-1.42%17.16%-0.69%23.99%13.81%18.7%20.63%20.16%
Gross Profit Growth %-1.3%1.13%17.74%0.43%20.12%-13.16%10.88%7.6%5.3%30.82%-21.8%0.72%17.07%3.37%-45.93%32.75%53.28%-11.88%-15.71%111.74%-26.63%1183.73%-107.87%2444.44%-102.43%64.24%-29.57%-9.92%3.58%148.61%
Operating Expenses3.38B2.9B3.25B2.9B2.93B2.27B2.29B2.35B2.26B1.69B1.71B1.63B1.58B1.49B1.5B1.41B3.11B2.64B2.64B1.13B1.15B1.16B1.29B-11.75B1.76B-12.78B-11.51B-13.76B-13.43B-13.45B-13.36B
OpEx / Revenue %22.8%19.72%23.23%22.06%24.67%19.66%21.39%21.87%22.33%17.7%18.27%17.89%16.27%14.98%16.04%15.79%33.79%31.19%33.82%11.47%11.04%11.74%13.05%-100.31%14.33%-97.57%-74.67%-84.44%-78.58%-78.22%-78.66%
Depreciation & Amortization53M70M67M73M51M54M60M68M79M88M77M84M83M101M125M79M78M86M78M64M48M54M75M7M-45M-115M-133M-35M51M88M-14.3M
Combined Ratio %89.4%88.99%91.35%88.43%93.15%87.34%92.32%88.64%90.49%86.27%87.86%93.97%87.55%87.15%90.83%90.27%87.92%93.63%107.21%87.64%84.1%98.36%94.92%1.11%97.17%3.12%1.34%1.75%2.72%1.15%1.18%
Operating Income1.57B1.62B1.21B1.52B814M1.46B821M1.22B964M1.31B1.14B549M1.21B1.28B859M871M1.11B540M-562M1.22B1.65B162M504M11.59B348M12.69B15.2B16.01B16.63B17B16.79B
Operating Margin %10.6%11.01%8.65%11.57%6.85%12.66%7.68%11.36%9.51%13.73%12.14%6.03%12.45%12.85%9.17%9.73%12.08%6.37%-7.21%12.36%15.9%1.64%5.08%98.89%2.83%96.88%98.66%98.25%97.28%98.85%98.82%
Operating Income Growth %-33.77%-20.22%86.49%-44.32%78.08%-32.87%26.87%-26.41%15.22%107.1%-54.52%-5.41%48.54%-1.38%-21.67%105.93%196.09%-145.99%-25.94%918.52%-67.86%-95.65%3229.02%-97.26%-16.53%-5.04%-3.72%-2.19%1.27%1510.48%
EBITDA1.62B1.69B1.28B1.59B865M1.52B881M1.29B1.04B1.4B1.21B633M1.29B1.38B984M950M1.19B626M-484M1.29B1.7B216M579M11.59B303M12.57B15.07B15.97B16.68B17.09B16.77B
EBITDA Margin %10.96%11.49%9.13%12.12%7.27%13.13%8.24%11.99%10.29%14.65%12.96%6.96%13.31%13.86%10.51%10.62%12.92%7.39%-6.21%13.01%16.36%2.19%5.83%98.95%2.46%96.01%97.8%98.04%97.58%99.36%98.74%
Interest Expense136M135M133M127M112M113M122M131M138M161M159M155M183M166M170M175M157M128M134M140M131M124M124M130M150M157M206M202M219M198M200.4M
Non-Operating Income-103M-135M-133M-127M-112M-113M-122M-131M-138M-161M-159M-155M-183M-166M-170M-175M-157M-128M-134M-140M-131M-124M-124M11.46B-143M12.53B15B15.81B16.41B16.8B16.59B
Pretax Income1.54B1.62B1.21B1.52B814M1.46B821M1.22B964M1.31B1.14B549M1.21B1.28B859M871M1.11B540M-562M1.22B1.65B162M504M-2.33B341M-2.29B1.73B-87M275M1.36B1.34B
Pretax Margin %10.38%11.01%8.65%11.57%6.85%12.66%7.68%11.36%9.51%13.73%12.14%6.03%12.45%12.85%9.17%9.73%12.08%6.37%-7.21%12.36%15.9%1.64%5.08%-19.91%2.77%-17.52%11.21%-0.53%1.61%7.9%7.92%
Income Tax211M342M252M313M132M278M131M223M151M411M278M70M319M361M239M242M333M57M-311M317M469M-105M31M-913M68M-744M550M-88M47M392M380.2M
Effective Tax Rate %13.72%21.11%20.81%20.62%16.22%19.02%15.96%18.23%15.66%31.37%24.45%12.75%26.43%28.29%27.82%27.78%29.95%10.56%55.34%25.94%28.42%-64.81%6.15%39.15%19.94%32.43%31.85%101.15%17.09%28.87%28.27%
Net Income1.33B1.28B959M1.21B682M1.18B690M1B813M899M859M479M691M937M628M612M690M419M-299M851M1.11B264M425M-1.42B163M-1.6B1.18B-172M228M966M964.8M
Net Margin %8.95%8.69%6.85%9.18%5.74%10.25%6.46%9.29%8.02%9.42%9.17%5.26%7.13%9.43%6.71%6.84%7.49%4.95%-3.83%8.61%10.68%2.68%4.28%-12.1%1.33%-12.25%7.67%-1.06%1.33%5.62%5.68%
Net Income Growth %48.27%33.26%-20.41%76.69%-42.4%71.59%-31%23%-9.57%4.66%79.33%-30.68%-26.25%49.2%2.61%-11.3%64.68%240.13%-135.14%-23.19%319.7%-37.88%129.99%-969.33%110.16%-235.79%787.21%-175.44%-76.4%0.12%27.45%
EPS (Diluted)4.914.693.524.432.504.412.532.532.983.303.171.772.553.472.332.272.281.10-1.113.134.050.761.40-6.320.72-8.186.40-0.681.195.201.72
EPS Growth %35.99%33.24%-20.54%77.2%-43.31%74.31%0%-15.1%-9.7%4.1%79.1%-30.59%-26.51%48.93%2.64%-0.44%107.27%199.1%-135.46%-22.72%432.89%-45.71%122.15%-977.78%108.8%-227.81%1041.18%-157.14%-77.12%202.33%-57.53%
EPS (Basic)-4.713.534.442.514.422.542.542.993.323.181.772.563.482.332.272.281.10-1.113.134.060.761.40-6.320.72-8.186.40-0.681.195.201.72
Diluted Shares Outstanding270.51M272.3M272.7M272.2M272.5M272.8M272.8M272.4M272.5M272.1M271.1M270.7M270.6M270.2M269.8M269.6M269.5M269.1M269.4M271.8M262.3M256M256M226.88M226.39M200.88M184.53M190.11M185.71M185.65M185.59M

Key Metrics

Growth RegimeDecelerating
ProfitabilityStable
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Social inflation litigation exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Deceleration Amid Competition

As reported in recent financial filings, CNA's revenue growth has decelerated from 10.6% in 2023Q4 to 3.0% by 2026Q1, suggesting that the company is facing increased competitive pressure or a cooling pricing environment within its core commercial and specialty insurance segments across the United States.

The consistent decline in year-over-year revenue growth rates indicates that the firm may be struggling to maintain its pricing power in a maturing market cycle. Investors should monitor whether this trend reflects a strategic choice to prioritize underwriting discipline over volume or a loss of market share in key professional liability niches.

Underwriting Discipline Maintains Combined Ratio

Based on the provided quarterly data, CNA has maintained a relatively stable combined ratio, which reached 91.8% in 2026Q1, demonstrating that the company continues to generate underwriting profit despite the volatility observed in the 2024Q4 period where the ratio spiked to 99.4%.

The ability to keep the combined ratio consistently below the 100% threshold suggests that the firm's actuarial pricing models remain effective in managing loss costs. However, the fluctuation in the loss ratio, which peaked at 70.2% in 2025Q2, warrants further investigation into whether social inflation is beginning to exert upward pressure on long-tail casualty claims.

2024Q4 Earnings Volatility Warrants Caution

According to the historical income statement data, 2024Q4 represented a significant inflection point where net income plummeted to $21 million, a sharp deviation from the typical quarterly performance, likely driven by non-recurring charges or adverse development in the legacy Life & Group run-off segment.

This period serves as a reminder of the inherent earnings volatility associated with the company's legacy liabilities. Analysts should interpret this as a potential indicator of the sensitivity of the bottom line to actuarial assumption changes, which can mask the underlying operational health of the core P&C business.

Litigation Tailwinds Threaten Long-Term Profitability

While current underwriting margins appear healthy, the persistent rise in loss ratios, which reached 69.2% on average over the last several quarters, suggests that CNA may be underestimating the impact of social inflation on its umbrella and general liability lines, potentially leading to future reserve deficiencies.

The reliance on historical loss data may prove insufficient if the frequency and severity of nuclear verdicts continue to accelerate. Investors should be wary that current profitability levels might be artificially supported by favorable prior-year reserve releases that could diminish as the litigation environment becomes increasingly hostile.

CNA — Frequently Asked Questions

Quick answers to the most common questions about buying CNA stock.

What was CNA Financial Corporation's (CNA) revenue in 2025?

For fiscal year 2025, CNA Financial Corporation (CNA) reported total revenue of $14.71B. This represents a 13.4% decline compared to $16.99B in 1996.

Is CNA Financial Corporation (CNA) profitable?

CNA Financial Corporation (CNA) is profitable, generating $1.28B in net income for the fiscal year ending 2025 with a net profit margin of 8.7%.

What is CNA Financial Corporation's operating profit margin?

CNA Financial Corporation (CNA) reported an operating income of $1.62B, resulting in an operating profit margin of 11.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is CNA Financial Corporation's gross profit and gross margin?

CNA Financial Corporation (CNA) generated $4.52B in gross profit for the year, representing a gross profit margin of 30.7%. This demonstrates the company's core pricing power and production efficiency.